ArticleInternational journal of endocrinology2019
Expression of Leptin Receptor and Effects of Leptin on Papillary Thyroid Carcinoma Cells.
Article in International journal of endocrinology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Obesity and thyroid cancer: mechanisms and clinical implications.Frontiers in nutrition · 2026Review
- Mechanistic Aspects of Inflammation and Oxidative Stress and Their Association With Thyroid Cancer Risk.Cancer medicine · 2025Review
- Human adipose-derived stem cells promote migration of papillary thyroid cancer cell via leptin pathway.Annals of medicine · 2024Article
- The Role of Body Mass Index (BMI) in Differentiated Thyroid Cancer: A Potential Prognostic Factor?Biomedicines · 2024Article
- Role of Different Variants of Leptin Receptor in Human Adrenal Tumor Types.International journal of molecular sciences · 2024Article
- Sex-dependent impact of obesity on aggressiveness of papillary thyroid cancer.Hormones (Athens, Greece) · 2024Article
- Diabetes Mellitus and Thyroid Cancers: Risky Correlation, Underlying Mechanisms and Clinical Prevention.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Review
- Metabolic syndrome and thyroid Cancer: risk, prognosis, and mechanism.Discover oncology · 2023Review
- Obesity and Thyroid Cancer Risk: An Update.International journal of environmental research and public health · 2022Review
- Adiponectin and leptin exert antagonizing effects on proliferation and motility of papillary thyroid cancer cell lines.Journal of physiology and biochemistry · 2021Article
- Impact of Overweight and Obesity on US Papillary Thyroid Cancer Incidence Trends (1995-2015).Journal of the National Cancer Institute · 2020Article
- Review
- The role of metabolic setting in predicting the risk of early tumour relapse of differentiated thyroid cancer (DTC).European journal of clinical nutrition · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundObesity has been hypothesized to contribute to the aggressiveness of thyroid cancer through the production of abnormal levels of serum adipokines. Leptin receptor (OB-R) expression has also been documented in papillary thyroid cancer (PTC).
aimIn this translational study, we analyzed
resultsIn TPC-1 and K1 cells, prolonged treatment with leptin (500 ng/ml for 96 h) resulted in a mild increase in the proliferation (about 20% over control only in K1 cells,
conclusionsThese results demonstrate leptin's role in mildly increasing the aggressive phenotype of PTC cells but without influencing the action of lenvatinib. Further studies will clarify whether it is possible to target OB-R, expressed in all aggressive PTCs, as an adjuvant treatment approach for these malignancies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.